今日盘中，思路迪医药股份（01244.HK）股价出现显著上涨，涨幅达5.91%，引发市场关注。该公司近期发布的年度业绩报告显示，尽管全年收入有所下降，但下半年销售较上半年增长15.9%，显示出积极的增长趋势。
根据思路迪医药股份发布的2024年年度业绩报告，公司实现收入4.46亿元，同比下降29.81%。尽管全年收入有所下滑，但公司在2024年下半年的销售表现较为亮眼，比上半年增长15.9%，这一数据反映出公司销售趋势正在向好发展。此外，公司的经调整年内全面亏损总额为1.67亿元，同比减少36.75%，显示出公司在成本控制方面取得了一定进展。
思路迪医药股份是一家专注于肿瘤慢病化治疗领域的生物制药公司。公司已成功将其首款产品恩维达推向市场，这是一种用于泛瘤种治疗的皮下注射PD-L1抑制剂。公司还拥有多个创新药物研发管线，涵盖从药物发现到临床试验的全流程。尽管面临激烈的市场竞争，但公司下半年销售的显著增长可能预示着其产品正逐步获得市场认可，这也可能是推动今日股价上涨的重要因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.